# FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

> **NCT01028820** · PHASE4 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 13 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT01028820
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028820, "FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01028820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*